Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models
Open accessThe DOI matches its Crossref record; 48 of the 50 references it cites were found in a registry or an index.
Abstract
Bacteria can be genetically engineered to kill specific pathogens or inhibit their virulence. We previously developed a synthetic genetic system that allows a laboratory strain of Escherichia coli to sense and kill Pseudomonas aeruginosa in vitro . Here, we generate a modified version of the system, including a gene encoding an anti-biofilm enzyme, and use the probiotic strain Escherichia coli Nissle 1917 as host. The engineered probiotic shows in vivo prophylactic and therapeutic activity against P. aeruginosa during gut infection in two animal models ( Caenorhabditis elegans and mice). These findings support the further development of engineered microorganisms with potential prophylactic and therapeutic activities against gut infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“For example, Hwang et. al. demonstrated that the EcN-based gastrointestinal delivery of anti-biofilm enzyme, dispersin B (DspB), resulted in a reduction of pre-colonized P. aeruginosa abundance in both nematode and murine models29.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [29]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Regulating effector expression in response to bacterial quorum sensing molecules29, pH30, specific carbon sources31–33, temperature34, or combinations of these signals may allow for exquisitely tuned effector functions in various intestinal microenvironments7.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products
Datsenko, K. A., & Wanner, B. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120163297 · Cited by 14,782
The Involvement of Cell-to-Cell Signals in the Development of a Bacterial Biofilm
Davies, D. G., Parsek, M. R., Pearson, J. P., Iglewski, B. H., Costerton, J. W., & Greenberg, E. P. (1998) · Science · doi:10.1126/science.280.5361.295 · Cited by 3,396
Ceri, H., Olson, M. E., Stremick, C., Read, R. R., Morck, D., & Buret, A. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.6.1771-1776.1999 · Cited by 2,155
Interdependence of Cell Growth and Gene Expression: Origins and Consequences
Scott, M., Gunderson, C. W., Mateescu, E. M., Zhang, Z., & Hwa, T. (2010) · Science · doi:10.1126/science.1192588 · Cited by 1,470
Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients
Smith, E. E., Buckley, D. G., Wu, Z., Saenphimmachak, C., Hoffman, L. R., D’Argenio, D. A., Miller, S. I., Ramsey, B. W., Speert, D. P., Moskowitz, S. M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602138103 · Cited by 1,319
Tan, M.-W., Mahajan-Miklos, S., & Ausubel, F. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.2.715 · Cited by 1,002
Synchronized cycles of bacterial lysis for in vivo delivery
Din, M. O., Danino, T., Prindle, A., Skalak, M., Selimkhanov, J., Allen, K., Julio, E., Atolia, E., Tsimring, L. S., Bhatia, S. N., et al. (2016) · Nature · doi:10.1038/nature18930 · Cited by 784
Refinement and standardization of synthetic biological parts and devices
Canton, B., Labno, A., & Endy, D. (2008) · Nature Biotechnology · doi:10.1038/nbt1413 · Cited by 753
The gastrointestinal tract. The “undrained abscess” of multiple organ failure
Marshall, J. C., Christou, N. V., & Meakins, J. L. (1993) · Annals of Surgery · doi:10.1097/00000658-199308000-00001 · Cited by 707
de Jonge, E., Schultz, M. J., Spanjaard, L., Bossuyt, P. M., Vroom, M. B., Dankert, J., & Kesecioglu, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14409-1 · Cited by 587
Cited by
Biofilms as Promoters of Bacterial Antibiotic Resistance and Tolerance
Uruén, C., Chopo-Escuin, G., Tommassen, J., Mainar-Jaime, R. C., & Arenas, J. (2020) · Antibiotics · doi:10.3390/antibiotics10010003 · Cited by 769
“aeruginosa gut infection in animal models [321].”
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Gurbatri, C. R., Lia, I., Vincent, R., Coker, C., Castro, S., Treuting, P. M., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0876 · Cited by 647
An ingestible bacterial-electronic system to monitor gastrointestinal health
Mimee, M., Nadeau, P., Hayward, A., Carim, S., Flanagan, S., Jerger, L., Collins, J., McDonnell, S., Swartwout, R., Citorik, R. J., et al. (2018) · Science · doi:10.1126/science.aas9315 · Cited by 606
Isabella, V. M., Ha, B. N., Castillo, M. J., Lubkowicz, D. J., Rowe, S. E., Millet, Y. A., Anderson, C. L., Li, N., Fisher, A. B., West, K. A., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4222 · Cited by 605
Synthetic Biology Tools to Engineer Microbial Communities for Biotechnology
McCarty, N. S., & Ledesma-Amaro, R. (2019) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.11.002 · Cited by 578
“While individual species have been engineered for therapeutic applications in vivo [86,87], it is only recently that synthetic microbial”
BackgroundChoi, K. R., Jang, W. D., Yang, D., Cho, J. S., Park, D., & Lee, S. Y. (2019) · Trends in Biotechnology · doi:10.1016/j.tibtech.2019.01.003 · Cited by 566
Developing a new class of engineered live bacterial therapeutics to treat human diseases
Charbonneau, M. R., Isabella, V. M., Li, N., & Kurtz, C. B. (2020) · Nature Communications · doi:10.1038/s41467-020-15508-1 · Cited by 523
Microbiome and Human Health: Current Understanding, Engineering, and Enabling Technologies
Aggarwal, N., Kitano, S., Puah, G. R. Y., Kittelmann, S., Hwang, I. Y., & Chang, M. W. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00431 · Cited by 508
Self-citationEngineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut
Praveschotinunt, P., Duraj-Thatte, A. M., Gelfat, I., Bahl, F., Chou, D. B., & Joshi, N. S. (2019) · Nature Communications · doi:10.1038/s41467-019-13336-6 · Cited by 463
Engineering bacteria for diagnostic and therapeutic applications
Riglar, D. T., & Silver, P. A. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.172 · Cited by 460
Antibiotic perturbations to the gut microbiome
Fishbein, S. R. S., Mahmud, B., & Dantas, G. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00933-y · Cited by 440
“Complementing such strategies, a wealth of scholarship highlights the translational potential of emerging microbiome restorative strategies, such as narrow-spectrum engineered probiotics 167,168,173,200,204,205 or defined FMTs 185–188 , Published online: 25 July 2023”
BackgroundMethodAdvancing functional and translational microbiome research using meta-omics approaches
Zhang, X., Li, L., Butcher, J., Stintzi, A., & Figeys, D. (2019) · Microbiome · doi:10.1186/s40168-019-0767-6 · Cited by 340
“[122], prebiotics [9], bacteriophages [123], or highly”
Cao, Z., Wang, X., Pang, Y., Cheng, S., & Liu, J. (2019) · Nature Communications · doi:10.1038/s41467-019-13727-9 · Cited by 337
Mining the microbiota for microbial and metabolite-based immunotherapies
Skelly, A. N., Sato, Y., Kearney, S., & Honda, K. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0144-5 · Cited by 306
Fleitas Martínez, O., Cardoso, M. H., Ribeiro, S. M., & Franco, O. L. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00074 · Cited by 304
Applications, challenges, and needs for employing synthetic biology beyond the lab
Brooks, S. M., & Alper, H. S. (2021) · Nature Communications · doi:10.1038/s41467-021-21740-0 · Cited by 286
Genetically stable CRISPR-based kill switches for engineered microbes
Rottinghaus, A. G., Ferreiro, A., Fishbein, S. R. S., Dantas, G., & Moon, T. S. (2022) · Nature Communications · doi:10.1038/s41467-022-28163-5 · Cited by 278
Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease
Scott, B. M., Gutiérrez-Vázquez, C., Sanmarco, L. M., da Silva Pereira, J. A., Li, Z., Plasencia, A., Hewson, P., Cox, L. M., O’Brien, M., Chen, S. K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01390-x · Cited by 280
Cryomicroneedles for transdermal cell delivery
Chang, H., Chew, S. W. T., Zheng, M., Lio, D. C. S., Wiraja, C., Mei, Y., Ning, X., Cui, M., Than, A., Shi, P., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00720-1 · Cited by 265
Probiotic strains detect and suppress cholera in mice
Mao, N., Cubillos-Ruiz, A., Cameron, D. E., & Collins, J. J. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao2586 · Cited by 261
Li, Z., Wang, Y., Liu, J., Rawding, P., Bu, J., Hong, S., & Hu, Q. (2021) · Advanced Materials · doi:10.1002/adma.202102580 · Cited by 244
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics
Lynch, J. P., Goers, L., & Lesser, C. F. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.02.002 · Cited by 230
Resilient living materials built by printing bacterial spores
González, L. M., Mukhitov, N., & Voigt, C. A. (2020) · Nature Chemical Biology · doi:10.1038/s41589-019-0412-5 · Cited by 224
A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies
Rodiño-Janeiro, B. K., Vicario, M., Alonso-Cotoner, C., Pascua-García, R., & Santos, J. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0673-5 · Cited by 214
“Also, the development of anEscherichia coli to sense and kill Pseudomonas aeruginosa in infections in animal models opens the possibility to specifically attack some species [133].”
BackgroundEngineering rhizobacteria for sustainable agriculture
Haskett, T. L., Tkacz, A., & Poole, P. S. (2021) · The ISME Journal · doi:10.1038/s41396-020-00835-4 · Cited by 199
Quorum sensing for population-level control of bacteria and potential therapeutic applications
Wu, S., Liu, J., Liu, C., Yang, A., & Qiao, J. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03326-8 · Cited by 189
Engineering Microbial Living Therapeutics: The Synthetic Biology Toolbox
Pedrolli, D. B., Ribeiro, N. V., Squizato, P. N., de Jesus, V. N., Cozetto, D. A., Tuma, R. B., Gracindo, A., Cesar, M. B., Freire, P. J. C., da Costa, A. F. M., et al. (2019) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.09.005 · Cited by 189
Mycoplasma pneumoniae Infections: Pathogenesis and Vaccine Development
Jiang, Z., Li, S., Zhu, C., Zhou, R., & Leung, P. H. M. (2021) · Pathogens · doi:10.3390/pathogens10020119 · Cited by 181
Applications of synthetic biology in medical and pharmaceutical fields
Yan, X., Liu, X., Zhao, C., & Chen, G.-Q. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01440-5 · Cited by 179
“aeruginosa.(146) The designed EcN was able to sense the biomarker N-acyl homoserine lactone produced by P.”
BackgroundDNA-based memory devices for recording cellular events
Sheth, R. U., & Wang, H. H. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0052-8 · Cited by 172
Bober, J. R., Beisel, C. L., & Nair, N. U. (2018) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-062117-121019 · Cited by 168
“(92, 93) demonstrates how synthetic biology can be applied to engineer probiotic bacteria to defend against pathogens.”
BackgroundEnhancing the tropism of bacteria via genetically programmed biosensors
Chien, T., Harimoto, T., Kepecs, B., Gray, K., Coker, C., Hou, N., Pu, K., Azad, T., Nolasco, A., Pavlicova, M., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00772-3 · Cited by 164
Genome editing for plant disease resistance: applications and perspectives
Yin, K., & Qiu, J.-L. (2019) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2018.0322 · Cited by 163
Tarín-Pelló, A., Suay-García, B., & Pérez-Gracia, M.-T. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2022.2078308 · Cited by 164
“This demonstrates the need for more studies that evaluate and better understand the mechanisms of action involved in the fight against AMRs, in addition to acquiring a deeper knowledge of the role that the microbiota has in the human being [58,63].”
BackgroundSynthetic Biology and Engineered Live Biotherapeutics: Toward Increasing System Complexity
Ozdemir, T., Fedorec, A. J. H., Danino, T., & Barnes, C. P. (2018) · Cell Systems · doi:10.1016/j.cels.2018.06.008 · Cited by 159
“, 2013), plus the incorporation of the anti-biofilm dispersin B protein (Hwang et al., 2017).”
BackgroundEngineering probiotics for therapeutic applications: recent examples and translational outlook
Aggarwal, N., Breedon, A. M. E., Davis, C. M., Hwang, I. Y., & Chang, M. W. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.02.016 · Cited by 154
Self-citationSiegerstetter, S.-C., Schmitz‐Esser, S., Magowan, E. A., Wetzels, S. U., Zebeli, Q., Lawlor, P. G., O’Connell, N. E., & Metzler-Zebeli, B. U. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187766 · Cited by 181
“Accordingly, some strains of Escherichia coli may confer beneficial physiological activities by reducing intestinal inflammation, increasing host innate immune functions or protecting the intestinal barrier against pathogens [40], which may have consequences for TBWG.”
BackgroundEngineering probiotics as living diagnostics and therapeutics for improving human health
Zhou, Z., Chen, X., Sheng, H., Shen, X., Sun, X., Yan, Y., Wang, J., & Yuan, Q. (2020) · Microbial Cell Factories · doi:10.1186/s12934-020-01318-z · Cited by 145
Ma, J., Lyu, Y., Liu, X., Jia, X., Cui, F., Wu, X., Deng, S., & Yue, C. (2022) · Microbial Cell Factories · doi:10.1186/s12934-022-01799-0 · Cited by 142
“coli Nissle 1917 to specifically kill pathogens by detecting the autoinducer N-acyl homoserine lactone (AHL) of Pseudomonas aeruginosa and releasing antibiotics and antibiofilm enzymes [26].”
BackgroundCell‐Based Delivery Systems: Emerging Carriers for Immunotherapy
Li, Z., Wang, Y., Ding, Y., Repp, L., Kwon, G. S., & Hu, Q. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100088 · Cited by 146
Synthetic gene circuits for the detection, elimination and prevention of disease
Sedlmayer, F., Aubel, D., & Fussenegger, M. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0215-0 · Cited by 151
Palmer, J. D., Piattelli, E., McCormick, B. A., Silby, M. W., Brigham, C. J., & Bucci, V. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00114 · Cited by 133
Adaptive Strategies of the Candidate Probiotic E. coli Nissle in the Mammalian Gut
Crook, N., Ferreiro, A. L., Gasparrini, A. J., Pesesky, M. W., Gibson, M. K., Wang, B., Sun, X., Condiotte, Z. J., Dobrowolski, S., Peterson, D. A., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.02.005 · Cited by 137
Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut
Lynch, J. P., González-Prieto, C., Reeves, A. Z., Bae, S., Powale, U., Godbole, N. P., Tremblay, J. M., Schmidt, F. I., Ploegh, H. L., Kansra, V. V., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.03.007 · Cited by 139
Game changers in science and technology - now and beyond
Betz, U. A. K., Arora, L., Assal, R. A., de Azevedo, H. F. Z., Baldwin, J., Becker, M. S., Bostock, S., Cheng, V. W. T., Egle, T., Ferrari, N., et al. (2023) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2023.122588 · Cited by 178
Synthetic Biology for Manipulating Quorum Sensing in Microbial Consortia
Stephens, K., & Bentley, W. E. (2020) · Trends in Microbiology · doi:10.1016/j.tim.2020.03.009 · Cited by 126
Self-citationEditing the microbiome the CRISPR way
Ramachandran, G., & Bikard, D. (2019) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2018.0103 · Cited by 138
Synthetic genetic circuits for programmable biological functionalities
Xia, P., Ling, H., Foo, J. L., & Chang, M. W. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.04.015 · Cited by 141
Self-citationTheranostic cells: emerging clinical applications of synthetic biology
McNerney, M. P., Doiron, K. E., Ng, T. L., Chang, T. Z., & Silver, P. A. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00383-3 · Cited by 141
Multiscale Evolutionary Dynamics of Host-Associated Microbiomes
Ferreiro, A., Crook, N., Gasparrini, A. J., & Dantas, G. (2018) · Cell · doi:10.1016/j.cell.2018.02.015 · Cited by 127
“This underscores the need to characterize the adaptation and lineage progression of human-associated microbes, including commensals and probiotics, in physiologically relevant environments (Durrer et al., 2017; Hudson et al., 2014; Hwang et al., 2017).”
Mukherjee, S., Joardar, N., Sengupta, S., & Sinha Babu, S. P. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.07.010 · Cited by 124
“to the secretion of antimicrobial peptide and inhibiting pathogen translocation [304].”
BackgroundGenetic circuit design automation for the gut resident species Bacteroides thetaiotaomicron
Taketani, M., Zhang, J., Zhang, S., Triassi, A. J., Huang, Y.-J., Griffith, L. G., & Voigt, C. A. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0468-5 · Cited by 124
Bacterial therapies at the interface of synthetic biology and nanomedicine
Hahn, J., Ding, S., Im, J., Harimoto, T., Leong, K. W., & Danino, T. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00119-4 · Cited by 139
Zong, X., Xiao, X., Shen, B., Jiang, Q., Wang, H., Lu, Z., Wang, F., Min, J., Min, J., Wang, F., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab343 · Cited by 135
“Bacterial infections are a major cause of both morbidity and mortality, with high costs both in the healthcare field and to society (1).”
BackgroundKoh, E., Hwang, I. Y., Lee, H. L., Sotto, R. D., Lee, J. W. J., Lee, Y. S., March, J. C., & Chang, M. W. (2022) · Nature Communications · doi:10.1038/s41467-022-31334-z · Cited by 118
Self-citationHrynyshyn, A., Simões, M., & Borges, A. (2022) · Antibiotics · doi:10.3390/antibiotics11010069 · Cited by 110
Genome editing of lactic acid bacteria: opportunities for food, feed, pharma and biotech
Börner, R. A., Kandasamy, V., Axelsen, A. M., Nielsen, A. T., & Bosma, E. F. (2019) · FEMS Microbiology Letters · doi:10.1093/femsle/fny291 · Cited by 106
Ha, J.-H., Hauk, P., Cho, K., Eo, Y., Ma, X., Stephens, K., Cha, S., Jeong, M., Suh, J.-Y., Sintim, H. O., et al. (2018) · Science Advances · doi:10.1126/sciadv.aar7063 · Cited by 104
“For example, researchers have exploited QS circuitry for the design and implementation of “smart” bacteria that target and destroy cancers and pathogens (6, 7).”
BackgroundSelf-citationQuorum Sensing Communication: Molecularly Connecting Cells, Their Neighbors, and Even Devices
Wang, S., Payne, G. F., & Bentley, W. E. (2020) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-101519-124728 · Cited by 110
Self-citationLuo, H., Wu, F. Q., Wang, X., Lin, S., Zhang, M., Cao, Z., & Liu, J. (2023) · Materials Today · doi:10.1016/j.mattod.2023.01.001 · Cited by 105
The role of the gut microbiota in the treatment of inflammatory bowel diseases
Aggeletopoulou, I., Konstantakis, C., Assimakopoulos, S. F., & Triantos, C. K. (2019) · Microbial Pathogenesis · doi:10.1016/j.micpath.2019.103774 · Cited by 119
Terrell, J. L., Tschirhart, T., Jahnke, J. P., Stephens, K., Liu, Y., Dong, H., Hurley, M. M., Pozo, M. R., McKay, R., Tsao, C. Y., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00878-4 · Cited by 113
Self-citationSynthetic biology-inspired cell engineering in diagnosis, treatment and drug development
Zhao, N., Song, Y., Xie, X., Zhu, Z., Duan, C., Nong, C., Wang, H., & Bao, R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01375-x · Cited by 121
“172 In the presence of 3OC 12 HSL, this E. coli strain triggers E7 lysozyme-mediated self-lysis releasing Pyocin S5 and Dispersin B that kills P. aeruginosa .”
BackgroundSynthetic biology in probiotic lactic acid bacteria: At the frontier of living therapeutics
Mays, Z. J., & Nair, N. U. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.01.028 · Cited by 99
Bacteria and bacterial derivatives as delivery carriers for immunotherapy
Kang, S., Nguyen, D.-H., Yoo, S. W., & Min, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114085 · Cited by 106
Intestinal Delivery of Probiotics: Materials, Strategies, and Applications
Li, C., Wang, Z., Xiao, H., & Wu, F. (2024) · Advanced Materials · doi:10.1002/adma.202310174 · Cited by 117
Redesigning regulatory components of quorum-sensing system for diverse metabolic control
Ge, C., Yu, Z., Sheng, H., Shen, X., Sun, X., Zhang, Y., Yan, Y., Wang, J., & Yuan, Q. (2022) · Nature Communications · doi:10.1038/s41467-022-29933-x · Cited by 102
Oral delivery of bacteria: Basic principles and biomedical applications
Li, S., Jiang, W., Zheng, C., Shao, D., Liu, Y., Huang, S., Han, J., Ding, J., Tao, Y., & Li, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.011 · Cited by 97
Microbial applications for sustainable space exploration beyond low Earth orbit
Koehle, A. P., Brumwell, S. L., Seto, E. P., Lynch, A. M., & Urbaniak, C. (2023) · npj Microgravity · doi:10.1038/s41526-023-00285-0 · Cited by 117
Geldart, K. G., Kommineni, S., Forbes, M., Hayward, M., Dunny, G. M., Salzman, N. H., & Kaznessis, Y. N. (2018) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10107 · Cited by 93
“in which EcN was engineered to produce the bacteriocin pyocin S5 and release the protein via cell lysis in response to a quorum sensing signal produced by the pathogen Pseudomonas aeruginosa .(22) This mode of release via cell lysis is common for the production of large bacteriocins produced by and targeting Gram-nega…”
BackgroundInducible cell-to-cell signaling for tunable dynamics in microbial communities
Miano, A., Liao, M. J., & Hasty, J. (2020) · Nature Communications · doi:10.1038/s41467-020-15056-8 · Cited by 94
The honey bee gut microbiota: strategies for study and characterization
Romero, S., Nastasa, A., Chapman, A., Kwong, W. K., & Foster, L. J. (2019) · Insect Molecular Biology · doi:10.1111/imb.12567 · Cited by 108
Yu, M., Hu, S., Tang, B., Yang, H., & Sun, D. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108202 · Cited by 96
The Prospects for the Therapeutic Implications of Genetically Engineered Probiotics
Mazhar, S. F., Afzal, M., Almatroudi, A., Munir, S., Ashfaq, U. A., Rasool, M., Raza, H., Munir, H. M. W., Rajoka, M. S. R., & Khurshid, M. (2020) · Journal of Food Quality · doi:10.1155/2020/9676452 · Cited by 99
“Antibiotic treatment can remove useful microorganisms and results in the emergence of resistant microbial strains [47].”
BackgroundAccelerated Amyloid Beta Pathogenesis by Bacterial Amyloid FapC
Javed, I., Zhang, Z., Adamčík, J., Andrikopoulos, N., Li, Y., Otzen, D. E., Lin, S., Mezzenga, R., Davis, T. P., Ding, F., et al. (2020) · Advanced Science · doi:10.1002/advs.202001299 · Cited by 93
Nougayrède, J.-P., Chagneau, C. V., Motta, J.-P., Bossuet-Greif, N., Belloy, M., Taieb, F., Gratadoux, J.-J., Thomas, M., Langella, P., & Oswald, E. (2021) · mSphere · doi:10.1128/msphere.00624-21 · Cited by 82
“enzyme against Pseudomonas aeruginosa (43) or a microcin induced upon sensing of Salmonella infection (44).”
BackgroundMethodSynthetic biology toolkits and applications in Saccharomyces cerevisiae
Chen, B., Lee, H. L., Heng, Y. C., Chua, N., Teo, W. S., Choi, W. J., Leong, S. S. J., Foo, J. L., & Chang, M. W. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.07.005 · Cited by 88
Self-citationZhao, C., Dong, H., Zhang, Y., & Li, Y. (2019) · npj Biofilms and Microbiomes · doi:10.1038/s41522-019-0092-7 · Cited by 80
Bacterially mediated drug delivery and therapeutics: Strategies and advancements
Wu, L., Bao, F., Li, L., Yin, X., & Hua, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114363 · Cited by 83
Modulation of gut‐microbiota through probiotics and dietary interventions to improve host health
Dasriya, V. L., Samtiya, M., Ranveer, S. A., Dhillon, H. S., Devi, N., Sharma, V., Nikam, P., Puniya, M., Chaudhary, P., Chaudhary, V., et al. (2024) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.13370 · Cited by 93
Durmusoglu, D., Al’Abri, I. S., Collins, S. P., Cheng, J., Eroglu, A., Beisel, C. L., & Crook, N. (2021) · ACS Synthetic Biology · doi:10.1021/acssynbio.0c00562 · Cited by 84
Singh, R. P., Shadan, A., & Ma, Y. (2022) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-022-09992-8 · Cited by 75
Shamoon, M., Martin, N. M., & O'Brien, C. L. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104344 · Cited by 78
Min, J., Yang, Y., Wu, Z., & Gao, W. F. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900125 · Cited by 89
Zuo, F., Chen, S., & Marcotte, H. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107654 · Cited by 73
Alterations in the intestinal microbiome associated with PCOS affect the clinical phenotype
Wang, L., Zhou, J., Gober, H.-J., Leung, W. T., Huang, Z., Pan, X., Li, C., Zhang, N., & Wang, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110958 · Cited by 87
Artificial intelligence and synthetic biology approaches for human gut microbiome
Kumar, P., Sinha, R., & Shukla, P. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1850415 · Cited by 71
“In another study, a probiotic strain E. coli Nissle 1917 was engineered to detect the pathogen-associated quorum-signal molecule excreted by P. aeruginosa through the quorum-sensing pathway (Hwang et al. 2017).”
BackgroundEngineered microbial systems for advanced drug delivery
Shen, H., Aggarwal, N., Wun, K. S., Lee, Y. S., Hwang, I. Y., & Chang, M. W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114364 · Cited by 76
Self-citationEmerging Frontiers in Microbiome Engineering
Inda, M. E., Broset, E., Lu, T. K., & de la Fuente‐Núñez, C. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.08.007 · Cited by 78
“Certain probiotics have been engineered to detect quorum-sensing molecules produced by pathogenic bacteria, for example, cholera autoinducer-1 [55], Staphylococcus autoinducer peptide-I [56], or Pseudomonas aeruginosa autoinducer N-acyl homoserine lactone [57].”
BackgroundCaenorhabditis Elegans and Probiotics Interactions from a Prolongevity Perspective
Roselli, M., Schifano, E., Guantario, B., Zinno, P., Uccelletti, D., & Devirgiliis, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205020 · Cited by 80
“Escherichia coli Nissle 1917 unknown [66]”
Bottom-Up Approaches to Synthetic Cooperation in Microbial Communities
Rodríguez Amor, D., & Dal Bello, M. (2019) · Life · doi:10.3390/life9010022 · Cited by 71
“coli to more abundant gut commensals [88,89], have experimentally been introduced in gut communities in order to deliver therapeutic molecules [90] and, in other cases, to detect cancer [91–93], inflammation [94], and signals secreted by pathogens [95,96].”
BackgroundEngineered Bacteria-Based Living Materials for Biotherapeutic Applications
Omer, R., Mohsin, M. Z., Mohsin, A., Mushtaq, B. S., Huang, X., Guo, M., Zhuang, Y., & Huang, J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.870675 · Cited by 77
Current Promising Strategies against Antibiotic-Resistant Bacterial Infections
Ye, J.-Z., & Chen, X. (2022) · Antibiotics · doi:10.3390/antibiotics12010067 · Cited by 91
Biosafety and biosecurity in Synthetic Biology: A review
Gómez‐Tatay, L., & Hernández‐Andreu, J. M. (2019) · Critical Reviews in Environmental Science and Technology · doi:10.1080/10643389.2019.1579628 · Cited by 79
“For example, E. coli has been successfully engineered to exhibit prophylactic activity against Pseudomonas aeruginosa in vivo, which has been demonstrated both in Caenorhabditis elegans and mice (Hwang et al., 2017).”
BackgroundCRISPR-Cas-Based Engineering of Probiotics
Liu, L., Helal, S. E., & Peng, N. (2023) · BioDesign Research · doi:10.34133/bdr.0017 · Cited by 93
“The development of genome engineering and synthetic biology has greatly promoted the construction of novel probiotic strains with desired functions, which has facilitated the treatment of metabolic disorders [11], inflammation [12], pathogen infection [13], and even cancer [14,15].”
BackgroundPirolli, N. H., Bentley, W. E., & Jay, S. M. (2021) · Advanced Biology · doi:10.1002/adbi.202000540 · Cited by 77
Self-citationTargeted Therapeutic Strategies in the Battle Against Pathogenic Bacteria
Yang, B., Fang, D., Lv, Q., Wang, Z., & Liu, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.673239 · Cited by 85
“Evaluation of the engineered probiotic strain in a C. elegans infection model and a mouse infection model showed good treatment results (Hwang et al., 2017).”
BackgroundMicrobiome engineering: engineered live biotherapeutic products for treating human disease
Rutter, J. W., Dekker, L., Owen, K. A., & Barnes, C. P. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1000873 · Cited by 83
“These include novel animal models (Hwang et al., 2017; Rutter et al., 2019), innovative organ-on-chip systems that try to mimic human tissues (Bein et al.”
BackgroundYang, S., Qiao, J., Zhang, M., Kwok, L. Y., Matijašić, B. B., Zhang, H., & Zhang, W. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.06.006 · Cited by 84
“In another study, the genome of Escherichia coli strain Nissle1917 was modified to enhance its anti-biofilm properties, leading to efficacy in both preventing and treating infections in animal models [40].”
Mohan, A. N., Balachandran, M., & Panicker, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-40916-9 · Cited by 68
Metadata
- Authors
- Hwang, I. Y., Koh, E., Wong, A., March, J. C., Bentley, W. E., Lee, Y. S., & Chang, M. W.
- Affiliations
- National University of Singapore (SG)
- Cornell University (US)
- University of Maryland, College Park (US)
- Corresponding author
- Chang, Matthew Wook
- ORCID
- Venue
- Nature Communications
- Published
- 2017-04-11
- Volume
- 8
- Issue
- 1
- Pages
- 15028-15028
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5394271
- OpenAlex
- W2605968366
- Cited by
- 472
- References
- 50
- Citations by year
- 2026: 44 · 2025: 53 · 2024: 51 · 2023: 55 · 2022: 68 · 2021: 44 · 2020: 54 · 2019: 53 · 2018: 41 · 2017: 9
- FWCI
- 31.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National University of Singapore (DPRT/943/09/14)
- National University Health System
- Defense Threat Reduction Agency (HDTRA1‐13‐0037, HDTRA1, DPRT/943/09/14)
- U.S. Air Force
- Medical Research Council
- National Medical Research Council (CBRG11nov109)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- engineered probiotics, Escherichia coli, Pseudomonas aeruginosa, intestinal infection, Escherichia coli Nissle 1917, prophylaxis, therapeutic activities, Caenorhabditis elegans, mouse model
- MeSH terms
- Microorganisms, Genetically-Modified, Animals, Disease Models, Animal, Escherichia coli, Female, Gastroenteritis, Genetic Engineering, Mice, Inbred ICR, Pseudomonas aeruginosa, Pseudomonas Infections, Virulence, Caenorhabditis elegans, Probiotics, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.